Moderna on IP collision course with US government
The company is at loggerheads with National Institutes of Health over inventorship of crucial covid vaccine technology
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.